AVIR compared with PMVP: revenue, margins and what each company keeps, and the suppliers and customers both name

AVIRAtea Pharmaceuticals, Inc.

Mkt capRevenueRevenue

PMVPPMV Pharmaceuticals, Inc.

Mkt capRevenueRevenue

Compare

AVIRAtea Pharmaceuticals, Inc.

PMVPPMV Pharmaceuticals, Inc.

Price

Mkt cap

Revenue

Earnings history

Not investment advice. Not a broker-dealer. Indices shown as ETF proxies. Supply-chain data CC BY 4.0; market data not redistributable.

Listed on One’s Vibe · live-checked · Oct ’26

last 4 reports each · paired by recencyMethod ›

AVIR

1 of 4at or beyond implied

Reportimpliedrealized× implied

Q2 FY26±11.0%▲+0.20%×0.02

May 13 '26±12.9%▼−16.91%×1.31

Q1 FY26±18.1%▲+11.13%×0.61

Jan 8 '26±24.5%▲+3.74%×0.15

PMVP1 of 4 reports

Reportimpliedrealized× implied

Q2 FY26—▲+3.70%—

= impliedAVIR realized, solidPMVP realized, hatchedOne scale, both sides: full bar = 25%× = |realized| ÷ impliedSource: market data

AVIRAtea Pharmaceuticals, Inc.

4.10▼−0.24%· post 4.10

Mkt cap$328.8M

PMVPPMV Pharmaceuticals, Inc.

1.37▲+4.72%· post 1.37

ClosedNov 2 '26

Mkt cap$73.2M

Compare

ClosedNov 2 '26

AVIRAtea Pharmaceuticals, Inc.

PMVPPMV Pharmaceuticals, Inc.

4.10▼−0.24%post 4.10

Price

1.37▲+4.72%post 1.37

$328.8M

Mkt cap

$73.2M

AVIR4.10▼−0.24%vsPMVP1.37▲+4.72%ClosedNov 2 '26